Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Complete Title: AGCT1531, Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
Trial Phase: III
Investigator: Abby Rosenberg
This partially randomized phase III trial studies how well active surveillance, bleomycin, carboplatin, etoposide, or cisplatin work in treating pediatric and adult patients with germ cell tumors. Active surveillance may help doctors to monitor subjects with low risk germ cell tumors after their tumor is removed. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Keywords:
Pediatric Cancers, Miscellaneous
Ovarian Cancer
Solid Tumors
Teratomas
Neoplasms, Germ Cell and Embryonal
Urogenital Neoplasms
Neoplasms, Glandular and Epithelial
Adenocarcinoma
Genital Neoplasms, Female
Carcinoma
Endocrine Gland Neoplasms
Adnexal Diseases
Trophoblastic Neoplasms
Gonadal Disorders
Carcinoma, Embryonal
Choriocarcinoma
Endodermal Sinus Tumor
Mesonephroma
Pregnancy Complications, Neoplastic
Pregnancy Complications
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
Pediatric
III
Abby Rosenberg
AGCT1531
NCT03067181
AGCT1531, Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors